Journal of Clinical Endocrinology & Metabolism, Vol 70, 1414-1419, Copyright © 1990 by Endocrine Society

ARTICLES

Serum inhibin concentrations before and during gonadotropin treatment in men with hypogonadotropic hypogonadism: physiological and clinical implications

RI McLachlan, DM Finkel, WJ Bremner and PJ Snyder
Medical Service, Veterans Administration Medical Center, Seattle, Washington 98108.

We measured by RIA the inhibin concentrations in the sera of 20 men with hypogonadotropic hypogonadism before and during treatment with gonadotropins in order to determine the role of gonadotropins in the control of inhibin secretion and the utility of the serum inhibin concentration in assessing the spermatogenic response to gonadotropin treatment in these patients. Before treatment the mean serum inhibin concentration in the 20 hypogonadotropic men as a group (391 +/- 49 U/L) was significantly lower (P less than 0.001) than that in 27 normal men (741 +/- 52 U/L). In the 7 men whose hypogonadism was of postpubertal onset, the mean serum inhibin concentration (559 +/- 69 U/L) was not significantly lower than that in normal men. In the 13 men whose hypogonadism was of prepubertal onset, the serum inhibin level was significantly lower [381 +/- 74 U/L (P less than 0.01) in the 7 without a history of cryptorchidism and 207 +/- 46 U/L (P less than 0.01) in the 6 with a history of cryptorchidism]. All 20 patients were azoospermic or severely oligospermic and had distinctly subnormal serum testosterone concentrations, even those whose serum inhibin values were normal. In the 7 patients with postpubertal hypogonadism, treatment with hCG alone for 6 months increased the serum testosterone concentration and maximum sperm count to normal, even though the previously normal inhibin concentration was not increased further. In the 13 patients with prepubertal hypogonadism, treatment with hCG alone increased the serum inhibin concentration, and combined treatment with hCG and human menopausal gonadotropin (hMG) increased inhibin further, to well within the normal range (742 +/- 143 U/L) in the patients without a history of cryptorchidism and to just within the normal range (487 +/- 96 U/L) in those with such a history. In the 7 patients with prepubertal hypogonadism but no history of cryptorchidism, treatment with hCG and hMG increased the maximum sperm count to normal in 5. In the 6 patients with prepubertal hypogonadism who did have a history of cryptorchidism, hCG and hMG treatment produced a normal sperm count in only 1. Of 12 patients whose serum inhibin level was more than 300 U/L before treatment, 11 developed a normal maximum sperm count in response to treatment, but of 8 patients whose inhibin concentration was less than 300 U/L before treatment, only 2 developed a normal sperm count in response to treatment (P less than 0.01).(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				D. A. van Tijn, E. J. Schroor, H. A. Delemarre-van de Waal, J. J. M. de Vijlder, and T. Vulsma Early Assessment of Hypothalamic-Pituitary-Gonadal Function in Patients with Congenital Hypothyroidism of Central Origin J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 104 - 109. [Abstract] [Full Text] [PDF]

				F. H. Pierik, J. T. M. Vreeburg, T. Stijnen, F. H. de Jong, and R. F. A. Weber Serum Inhibin B as a Marker of Spermatogenesis J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3110 - 3114. [Abstract] [Full Text]

				A.-M. Andersson, J. Toppari, A.-M. Haavisto, J. H. Petersen, T. Simell, O. Simell, and N. E. Skakkebæk Longitudinal Reproductive Hormone Profiles in Infants: Peak of Inhibin B Levels in Infant Boys Exceeds Levels in Adult Men J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 675 - 681. [Abstract] [Full Text]

				A.-M. Andersson, A. Juul, J. H. Petersen, J. Muller, N. P. Groome, and N. E. Skakkebak Serum Inhibin B in Healthy Pubertal and Adolescent Boys: Relation to Age, Stage of Puberty, and Follicle-Stimulating Hormone, Luteinizing Hormone, Testosterone, and Estradiol Levels J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 3976 - 3981. [Abstract] [Full Text] [PDF]

				C. F. Minto, C. Howe, S. Wishart, A. J. Conway, and D. J. Handelsman Pharmacokinetics and Pharmacodynamics of Nandrolone Esters in Oil Vehicle: Effects of Ester, Injection Site and Injection Volume J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 93 - 102. [Abstract] [Full Text]